| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4808 | 2014 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4649 | 2013 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 3002 | 2015 |
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ... Journal of clinical oncology 30 (15), 1796-1804, 2012 | 2986 | 2012 |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2539 | 2019 |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 2388 | 2019 |
| Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer C Denkert, S Loibl, A Noske, M Roller, BM Müller, M Komor, J Budczies, ... Journal of clinical oncology 28 (1), 105-113, 2010 | 2037 | 2010 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1920 | 2018 |
| Palbociclib in hormone-receptor–positive advanced breast cancer NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ... New England Journal of Medicine 373 (3), 209-219, 2015 | 1811 | 2015 |
| Association analysis identifies 65 new breast cancer risk loci K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ... Nature 551 (7678), 92-94, 2017 | 1508 | 2017 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1481 | 2020 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1409 | 2014 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1329 | 2017 |
| Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ... New England Journal of Medicine 384 (25), 2394-2405, 2021 | 1324 | 2021 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1232 | 2020 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1199 | 2021 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1182 | 2018 |
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ... The lancet oncology 15 (7), 747-756, 2014 | 1163 | 2014 |
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... Journal of clinical oncology 33 (9), 983-991, 2015 | 1158 | 2015 |
| HER2-positive breast cancer S Loibl, L Gianni The Lancet 389 (10087), 2415-2429, 2017 | 1087 | 2017 |
Carsten DenkertProfessor of Pathology, Philipps-University Marburg, Germanyuni-marburg.de üzerinde doğrulanmış e-posta adresine sahip